AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22619063 — intervention group
Group type: COMPARATOR
Intervention: Week 12 HCV RNA level of 148 IU/mL
Number of subjects: 681
Study 22619063 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of stopping rules (HCV RNA level ≥ 100 IU/mL at week 12 and detectable HCV RNA at week 24)
Number of subjects: 681
Study 20529318 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor recreational physical activity (PA)
Number of subjects: 999
Study 20529318 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing outdoor recreational PA
Number of subjects: 999
Study 20529318 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing outdoor recreational PA among women
Number of subjects: 999
Study 20529318 — intervention group
Group type: EXPERIMENTAL
Intervention: Age influence on outdoor recreational PA
Number of subjects: 999
Study 18996870 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP (UNICEF/WHO/UNU international multiple micronutrient preparation)
Number of subjects: 1426
Study 18996870 — intervention group
Group type: EXPERIMENTAL
Intervention: UNIMMAP
Number of subjects: 1426
Study 16970099 — intervention group
Group type: EXPERIMENTAL
Intervention: Shufei Granule (SG) 10 g 3 times a day orally, in addition to control treatment.
Number of subjects: 100
Study 16970099 — intervention group
Group type: COMPARATOR
Intervention: Fleroxacin 0.2 g twice per day by intravenous dripping and diprophylline 0.2 g 3 times per day orally (Control group).
Number of subjects: 100
Study 12913678 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic therapy
Number of subjects: 0
Study 12913678 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidant and micronutrient therapy
Number of subjects: 0
Study 12913678 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose regulation
Number of subjects: 0
Study 12913678 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancement of gut motility
Number of subjects: 0
Study 12913678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia/reperfusion injury management
Number of subjects: 0
Study 10549446 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 200
Study 10549446 — intervention group
Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 200
Study 8694015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal oil (0.8 g AA, 0.6 g DHA)
Number of subjects: 32
Study 8694015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal oil (2.2 g AA, 1.7 g DHA)
Number of subjects: 32
Study 8694015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fungal oil (3.6 g AA, 2.9 g DHA)
Number of subjects: 32
Study 8694015 — intervention group
Group type: COMPARATOR
Intervention: Fungal oil (0 g AA, 0 g DHA)
Number of subjects: 32
Study 1859514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 3330
Study 1859514 — intervention group
Group type: COMPARATOR
Intervention: Digitalis
Number of subjects: 3330
Study 1859514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine and Digitalis (combined)
Number of subjects: 3330
Study 6601789 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency TENS (100 Hz)
Number of subjects: 62
Study 6601789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency TENS (2 Hz)
Number of subjects: 62
Study 6601789 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 62
Study 6601789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical vibratory stimulation
Number of subjects: 62
Study 31752813 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch-and-rinse + adhesive (ER)
Number of subjects: 150
Study 31752813 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective enamel etch + adhesive (SEE)
Number of subjects: 150
Study 31752813 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive (SE)
Number of subjects: 150
Study 30384375 — intervention group
Group type: EXPERIMENTAL
Intervention: Palosuran 500 mg b.i.d.
Number of subjects: 24
Study 30384375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 27260129 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg and tolterodine ER 4 mg per day
Number of subjects: 220
Study 27260129 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg and tolterodine ER 4 mg per day
Number of subjects: 220
Study 24839034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,470 nm diode laser
Number of subjects: 20
Study 24839034 — intervention group
Group type: COMPARATOR
Intervention: 940 nm diode laser
Number of subjects: 20
Study 22443848 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program
Number of subjects: 331
Study 19531946 — intervention group
Group type: EXPERIMENTAL
Intervention: MPM0‐III
Number of subjects: 124171
Study 19531946 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup models
Number of subjects: 124171
Study 17654694 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa 100 mg t.i.d. with sarizotan 5 mg b.i.d.
Number of subjects: 16
Study 17654694 — intervention group
Group type: COMPARATOR
Intervention: Levodopa 100 mg t.i.d. without sarizotan
Number of subjects: 16
Study 15342853 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypothermia after inpatient pediatric cardiac arrest
Number of subjects: 76
Study 11252121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding placement during index hospitalization
Number of subjects: 99
Study 11252121 — intervention group
Group type: COMPARATOR
Intervention: No tube feeding (31% left without a feeding tube)
Number of subjects: 99
Study 11252121 — intervention group
Group type: EXPERIMENTAL
Intervention: Admitting diagnosis of infection
Number of subjects: 99
Study 11252121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 99
Study 15512184 — intervention group
Group type: EXPERIMENTAL
Intervention: Alora (0.1 mg/day)
Number of subjects: 24
Study 15512184 — intervention group
Group type: COMPARATOR
Intervention: Estraderm (0.1 mg/day)
Number of subjects: 24
Study 8087189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 10 mg
Number of subjects: 19
Study 8087189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (Ned) 4 mg
Number of subjects: 19
Study 8087189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2679978 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine 7 micrograms.kg-1.min-1 (group D)
Number of subjects: 93
Study 2679978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 93
Study 1252881 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-held medical records
Number of subjects: 278
Study 1252881 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital notes
Number of subjects: 278
Study 29325753 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypothermia (target 32‐34°C) for 24 hours followed by normothermia (36‐38°C) for 48 hours
Number of subjects: 436
Study 29325753 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal management
Number of subjects: 436
Study 26821045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric load of 700 kcal/500 mL
Number of subjects: 37
Study 26821045 — intervention group
Group type: COMPARATOR
Intervention: Gastric load of 100 kcal/500 mL
Number of subjects: 37
Study 26821045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral exposure duration of 8 min
Number of subjects: 37
Study 26821045 — intervention group
Group type: COMPARATOR
Intervention: Oral exposure duration of 1 min
Number of subjects: 37
Study 24837113 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap and water, complemented with the use of hand sanitizer (Experimental Group)
Number of subjects: 1609
Study 24837113 — intervention group
Group type: COMPARATOR
Intervention: Usual handwashing procedure (Control Group)
Number of subjects: 1609
Study 21825081 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation-based management strategy (sputum eosinophils)
Number of subjects: 55
Study 21825081 — intervention group
Group type: COMPARATOR
Intervention: Symptom-based management strategy
Number of subjects: 55
Study 21031289 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based specific stabilizing exercises targeting local trunk muscles
Number of subjects: 88
Study 21031289 — intervention group
Group type: COMPARATOR
Intervention: Single telephone contact with a physiotherapist (Control)
Number of subjects: 88
Study 17118686 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/4.5 microg, two inhalations twice daily
Number of subjects: 673
Study 17118686 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol DPI 160/4.5 microg, two inhalations twice daily
Number of subjects: 673
Study 17118686 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI
Number of subjects: 673
Study 17118686 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol DPI
Number of subjects: 673
Study 16544967 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil (5 mg)
Number of subjects: 17
Study 16544967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12568835 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 40
Study 11007222 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (DeNoltab 120 mg, amoxycillin 500 mg, and metronidazole 300 mg four times daily)
Number of subjects: 120
Study 11007222 — intervention group
Group type: COMPARATOR
Intervention: DeNoltab 120 mg four times daily alone
Number of subjects: 120
Study 8632537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined neoadjuvant intravesical chemotherapy and local hyperthermia (group 1)
Number of subjects: 52
Study 8632537 — intervention group
Group type: COMPARATOR
Intervention: Intravesical chemotherapy alone (group 2)
Number of subjects: 52
Study 1363892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy before surgery for stage IIIA NSCLC
Number of subjects: 0
Study 1363892 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs (Navelbine, taxol, campthotecine) for NSCLC chemotherapy
Number of subjects: 0
Study 1363892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose intensity improvement with growth factors for SCLC
Number of subjects: 0
Study 1363892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionation of therapy for SCLC
Number of subjects: 0
Study 1363892 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation for SCLC
Number of subjects: 0
Study 6302649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless skin closure using Op‐Site skin closures
Number of subjects: 51
Study 6302649 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcuticular absorbable (Dexon) suture
Number of subjects: 51
Study 31138728 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubing resistance training
Number of subjects: 28
Study 31138728 — intervention group
Group type: COMPARATOR
Intervention: Weight-machine training (conventional resistance group)
Number of subjects: 28
Study 28842997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir and paritaprevir/ritonavir without ribavirin for 12 weeks
Number of subjects: 204
Study 28842997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir and paritaprevir/ritonavir with ribavirin for 16 weeks
Number of subjects: 204
Study 26098737 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 321
Study 26098737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 321
Study 26098737 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-Cognitive Only (CPT-C)
Number of subjects: 321
Study 26098737 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Accounts (WA)
Number of subjects: 321
Study 25155608 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 0
Study 25155608 — intervention group
Group type: COMPARATOR
Intervention: ritonavir-boosted lopinavir (LPV/r)
Number of subjects: 0
Study 25155608 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EFV and LPV/r
Number of subjects: 0
Study 22289222 — intervention group
Group type: EXPERIMENTAL
Intervention: Insemination at 56 h after CIDR removal
Number of subjects: 1098
Study 22289222 — intervention group
Group type: COMPARATOR
Intervention: Insemination at 72 h after CIDR removal
Number of subjects: 1098
Study 20732608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomically designed facemask
Number of subjects: 32
Study 20732608 — intervention group
Group type: COMPARATOR
Intervention: Standard facemask
Number of subjects: 32
Study 17524796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise therapy
Number of subjects: 108
Study 17524796 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-placebo
Number of subjects: 108
Study 17524796 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study 16272048 — intervention group
Group type: EXPERIMENTAL
Intervention: ECCE (conventional extracapsular cataract surgery)
Number of subjects: 186
Study 16272048 — intervention group
Group type: EXPERIMENTAL
Intervention: SICS (manual small‐incision cataract surgery)
Number of subjects: 186
Study 16272048 — intervention group
Group type: EXPERIMENTAL
Intervention: PE (phacoemulsification)
Number of subjects: 186
Study 11863478 — intervention group
Group type: EXPERIMENTAL
Intervention: Transferrin receptor-ferritin index (TR-F index)
Number of subjects: 63
Study 11863478 — intervention group
Group type: COMPARATOR
Intervention: Routine blood tests (serum iron, ferritin, and transferrin saturation levels)
Number of subjects: 63
Study 9988416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonically guided multifetal pregnancy reduction using a modified technique (no KCl, aspirating embryonic parts)
Number of subjects: 75
Study 9988416 — intervention group
Group type: COMPARATOR
Intervention: Nonreduced twins
Number of subjects: 75
Study 9988416 — intervention group
Group type: COMPARATOR
Intervention: Nonreduced triplets and quadruplets
Number of subjects: 75
Study 7486096 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% glucose
Number of subjects: 270
Study 7486096 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine in 8.5% glucose
Number of subjects: 270
Study 2268867 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of cefuroxime axetil orally (250 mg q12h)
Number of subjects: 185
Study 2268867 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of cefuroxime axetil orally (500 mg q12h)
Number of subjects: 185
Study 2268867 — intervention group
Group type: COMPARATOR
Intervention: 1,500 mg of cefaclor orally (500 mg q8h)
Number of subjects: 185
Study 6108248 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring-loaded clip
Number of subjects: 299
Study 6108248 — intervention group
Group type: COMPARATOR
Intervention: Tubal ring
Number of subjects: 299
Study 30925126 — intervention group
Group type: EXPERIMENTAL
Intervention: Personally tailored, automated telephone symptom management intervention
Number of subjects: 556
Study 30925126 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced with a nontailored newsletter about symptom management
Number of subjects: 556
Study 27527354 — intervention group
Group type: EXPERIMENTAL
Intervention: DPBN-8 Gy (dose range between 6 and 10 Gy)
Number of subjects: 0
Study 27527354 — intervention group
Group type: COMPARATOR
Intervention: ConvRT-8 Gy (conventionally planned radiotherapy)
Number of subjects: 0
Study 27527354 — intervention group
Group type: EXPERIMENTAL
Intervention: DPBN-16 Gy (dose range between 14 and 18 Gy)
Number of subjects: 0
Study 25591433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) group
Number of subjects: 84
Study 25591433 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate solution (RL) group
Number of subjects: 84
Study 23673291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride (HCl) extended release (ER) tablets (test formulation)
Number of subjects: 0
Study 21146429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine infusion
Number of subjects: 31
Study 21146429 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 31
Study 19514189 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming acupuncture group (needles warmed by burning moxa)
Number of subjects: 90
Study 19514189 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (Nimesulide tablets)
Number of subjects: 90
Study 19514189 — intervention group
Group type: COMPARATOR
Intervention: Point-injection group (Anisodamine injected)
Number of subjects: 90
Study 17339748 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.33 mg/day
Number of subjects: 20
Study 17339748 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 15506597 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative tests (routine medical tests and electrocardiograms)
Number of subjects: 1276
Study 15506597 — intervention group
Group type: COMPARATOR
Intervention: No preoperative tests
Number of subjects: 1276
Study 11678486 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook alone
Number of subjects: 588
Study 11678486 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tailoring using onsite computer kiosks
Number of subjects: 588
Study 11678486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both computers and staff consultation
Number of subjects: 588
Study 9152195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscope (CCF)
Number of subjects: 140
Study 9152195 — intervention group
Group type: COMPARATOR
Intervention: Normal colonoscope (NCF)
Number of subjects: 140
Study 9152195 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection using transparent cap-fitted endoscope (EMRC)
Number of subjects: 140
Study 9152195 — intervention group
Group type: COMPARATOR
Intervention: Conventional strip biopsy
Number of subjects: 140
Study 8432142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 15
Study 8432142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3434997 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 100
Study 28975353 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported telemonitoring intervention (self-measurement and transmission of glucose results to clinicians)
Number of subjects: 321
Study 27458809 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported telemonitoring intervention
Number of subjects: 321
Study 27458809 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 321
Study 24742587 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE programme (12-week exercise intervention)
Number of subjects: 84
Study 24742587 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 84
Study 22044077 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 96
Study 22044077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 20838060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg infused over 15 minutes every 3-4 weeks
Number of subjects: 14
Study 18479280 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30
Number of subjects: 0
Study 18479280 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 17064504 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (ONCAB)
Number of subjects: 72
Study 17064504 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 72
Study 17064504 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative condition
Number of subjects: 72
Study 17064504 — intervention group
Group type: COMPARATOR
Intervention: Post-operative condition (3 months)
Number of subjects: 72
Study 17064504 — intervention group
Group type: COMPARATOR
Intervention: Post-operative condition (6 months)
Number of subjects: 72
Study 17064504 — intervention group
Group type: COMPARATOR
Intervention: Depressive group
Number of subjects: 72
Study 17064504 — intervention group
Group type: COMPARATOR
Intervention: Depression group characteristics
Number of subjects: 72
Study 14636090 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Resistance Exercise (HRE) - 5 squats at 85% of 1 repetition maximum (1RM)
Number of subjects: 8
Study 14636090 — intervention group
Group type: COMPARATOR
Intervention: Control (no-HRE)
Number of subjects: 8
Study 11769903 — intervention group
Group type: EXPERIMENTAL
Intervention: Token exchange reinforcement technique
Number of subjects: 5
Study 11769903 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal praise paired with token exchange reinforcement technique
Number of subjects: 5
Study 9403034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous vegetables
Number of subjects: 8
Study 9403034 — intervention group
Group type: COMPARATOR
Intervention: Non-cruciferous vegetables
Number of subjects: 8
Study 9403034 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 rapid phenotype
Number of subjects: 8
Study 9403034 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1- subjects
Number of subjects: 8
Study 8240477 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream over the proposed epidural site for a minimum period of 5 min (mean 9.1 min)
Number of subjects: 60
Study 8240477 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin bleb and subcutaneous injection of lignocaine 2% (1 ml)
Number of subjects: 60
Study 8240477 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin bleb with additional lignocaine 2% (2 ml) infiltrated into the supra‐ and interspinous ligaments using a 23 G needle
Number of subjects: 60
Study 8240477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 2826064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg orally)
Number of subjects: 6
Study 2826064 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg subcutaneous)
Number of subjects: 6
Study 2826064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 6